The strong financial performance suggests underlying business strength, but the pending acquisition by Boston Scientific creates significant uncertainty about the company's future as an independent entity and its ability to execute on its current trajectory.
Price Chart
Executive Summary
Penumbra reported strong 2025 full-year financial results with revenue of $1.4 billion (up 17.5% YoY) and net income of $177.7 million, driven by growth in both thrombectomy and embolization/access products. However, the company will not provide 2026 guidance due to its pending acquisition by Boston Scientific, which also led to the cancellation of its earnings call.
Key Financial Metrics
Key Facts
- Revenue of $1.4037 billion for full-year 2025, up 17.5% YoY
- Net income of $177.7 million for full-year 2025, a significant improvement from $14 million in 2024
- Income from operations increased to $189.2 million from $9.3 million in 2024
- Company will not provide 2026 financial guidance due to pending acquisition by Boston Scientific
- Company canceled its earnings call due to the pending acquisition
Financial Impact
Revenue increased by $209 million YoY, net income increased by $163.7 million YoY
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Thrombectomy | $947.9M | +16.2% |
| Embolization and Access | $455.7M | +20.2% |
Risk Factors
- Pending acquisition by Boston Scientific may not close as expected
- Loss of operational independence and potential integration challenges
- Uncertainty around future guidance and strategic direction
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (PEN) — Batch item 1 | 0001321732-26-000006 |
| Document: pen-20260225.htm | 0001321732-26-000006 |
| Document: 0001321732-26-000006-index-headers.html | 0001321732-26-000006 |
| Document: 0001321732-26-000006-index.html | 0001321732-26-000006 |
| Document: 0001321732-26-000006.txt | 0001321732-26-000006 |
| 8-K Filing (PEN) — Batch item 6 | 0001321732-26-000006 |
| Document: pen-20260225.htm | 0001321732-26-000006 |
| Document: 0001321732-26-000006-index-headers.html | 0001321732-26-000006 |
| CONTEXT: Previous Earnings (2026-02-25) | 0001321732-26-000006 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 30, 2026 9w ago | Press Release | $321.19 $321.68 | ▼ −0.15% | ▲ +2.84% | $317.55 (+1.13%) |
May 7, 2026 21w ago | 425 | $324.65 $319.37 | ▼ −1.63% | ▼ −4.76% | $317.55 (−2.19%) |
May 6, 2026 21w ago | 8-K | $324.65 $319.37 | ▲ +1.63% | ▲ +4.76% | $317.55 (+2.19%) |
Apr 29, 2026 22w ago | DEFA14A | $326.48 $318.30 | ▼ −2.51% | ▼ −7.73% | $317.55 (−2.74%) |
Apr 17, 2026 24w ago | 425 | $329.71 $326.54 | ▼ −0.96% | ▼ −5.16% | $317.55 (−3.69%) |
Apr 1, 2026 26w ago | DEFM14A | $330.36 $326.48 | ▼ −1.17% | ▼ −11.05% | $317.55 (−3.88%) |
Feb 25, 2026 31w ago | 8-K | $338.67 $336.27 | ▼ −0.71% | ▲ +4.53% | $317.55 (−6.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access